They may delay the onset of cognitive decline in persons at risk for AD due to comorbidities shown to contribute to inflammaging, such as diabetes, obesity, or hypertension, while in later stages, they could be used as add-on strategies together with the already approved treatments (which offer only limited benefit) or with Aβ- or tau-targeted therapies. This evidence concerns the gene MAPT and obesity disorder.